RAF/RAS oncogenes and mismatch-repair status
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Genes of the RAF family encode kinases that are regulated by Ras and mediate cellular responses to growth signals. Activating mutations in one RAF gene, BRAF, have been found in a high proportion of melanomas and in a small fraction of other cancers. Here we show that BRAF mutations in colorectal cancers occur only in tumours that do not carry mutations in a RAS gene known as KRAS, and that BRAF mutation is linked to the proficiency of these tumours in repairing mismatched bases in DNA. Our results not only provide genetic support for the idea that mutations in BRAF and KRAS exert equivalent effects in tumorigenesis, but also emphasize the role of repair processes in establishing the mutation spectra that underpin human cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of BRAF V600E mutations in mCRC is 8–10%, and they occur only in KRAS-WT mCRC [159,160].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [160]
Citations
Cites
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Lessons from hereditary colorectal cancer
Kinzler, K. W., & Vogelstein, B. (1996) · Cell · doi:10.1016/s0092-8674(00)81333-1 · Cited by 4,919
Self-citationStabilization of β-Catenin by Genetic Defects in Melanoma Cell Lines
Rubinfeld, B., Robbins, P., El-Gamil, M., Albert, I., Porfiri, E., & Polakis, P. (1997) · Science · doi:10.1126/science.275.5307.1790 · Cited by 1,223
Mutational analysis of the APC/beta-catenin/Tcf pathway in colorectal cancer.
Sparks, A. B., Morin, P. J., Vogelstein, B., & Kinzler, K. W. (1998) · PubMed · Cited by 1,008
Self-citationDifferential Regulation of Raf-1, A-Raf, and B-Raf by Oncogenic Ras and Tyrosine Kinases
Marais, R., Light, Y., Paterson, H. F., Mason, C. S., & Marshall, C. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.7.4378 · Cited by 456
Mechanisms underlying losses of heterozygosity in human colorectal cancers
Thiagalingam, S., Laken, S., Willson, J. K. V., Markowitz, S. D., Kinzler, K. W., Vogelstein, B., & Lengauer, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051625398 · Cited by 228
Self-citationPrevalence of somatic alterations in the colorectal cancer cell genome
Wang, T.-L., Rago, C., Silliman, N., Ptak, J., Markowitz, S., Willson, J. K. V., Parmigiani, G., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.261714699 · Cited by 177
Self-citationOncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors
Storm, S. M., & Rapp, U. R. (1993) · Toxicology Letters · doi:10.1016/0378-4274(93)90056-4 · Cited by 53
Research works printed but not linked: 2
- Sparks, A. B., Morin, P. J., Vogelstein, B. & Kinzler, K. W. Cancer Res. 58, 1130–1134 (1998).
- Markowitz, S. J. Clin. Oncol. 18 (suppl.), 75–80 (2000).
Cited by
Items 501–600 of 999
Oikonomou, E., Makrodouli, E., Evagelidou, M., Joyce, T., Probert, L., & Pintzas, A. (2009) · Neoplasia · doi:10.1593/neo.09514 · Cited by 53
BRAF and RKIP are significantly decreased in cutaneous squamous cell carcinoma
Zaravinos, A., Kanellou, P., Baritaki, S., Bonavida, B., & Spandidos, D. A. (2009) · Cell Cycle · doi:10.4161/cc.8.9.8308 · Cited by 45
Detection of Mutant BRAF Alleles in the Plasma of Patients with Metastatic Melanoma
Yancovitz, M., Yoon, J., Mikhail, M., Gai, W., Shapiro, R. L., Berman, R. S., Pavlick, A. C., Chapman, P. B., Osman, I., & Polsky, D. (2007) · Journal of Molecular Diagnostics · doi:10.2353/jmoldx.2007.060135 · Cited by 44
Larki, P., Gharib, E., Taleghani, M. Y., Khorshidi, F., Mojarad, E. N., & Asadzadeh Aghdaei, H. (2017) · PubMed Central · doi:10.22074/cellj.2017.5123 · Cited by 57
“BRAF mutations have been recently reported in 5 to 15% of CRC cases (21-23).”
BackgroundMutational analysis of the BRAF, RAS and EGFR genes in human adrenocortical carcinomas
Kotoula, V., Sozopoulos, E., Litsiou, H., Fanourakis, G., Κoletsa, T., Voutsinas, G. E., Tseleni‐Balafouta, S., Mitsiades, C. S., Wellmann, A., & Mitsiades, N. (2009) · Endocrine Related Cancer · doi:10.1677/erc-08-0101 · Cited by 44
“2002) and colorectal (Rajagopalan et al. 2002) carcinomas, and in melanoma (Houben et al.”
BackgroundCen, S., Liu, K., Zheng, Y., Shan, J., Jing, C., Gao, J., Pan, H., Bai, Z., & Liu, Z. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.705060 · Cited by 45
RAB32 hypermethylation and microsatellite instability in gastric and endometrial adenocarcinomas
Shibata, D., Mori, Y., Cai, K., Zhang, L., Yin, J., Elahi, A. H., Hamelin, R., Wong, Y. F., Lo, W. K., Chung, T. K. H., et al. (2006) · International Journal of Cancer · doi:10.1002/ijc.21912 · Cited by 44
“However, activating mutations of BRAF are strongly associated with these tumors and may functionally compensate for the lack of K-ras mutation.(39) Conversely, in gastric cancers, BRAF mutations are exceedingly rare and it appears that K-ras mutation is strongly associated with microsatellite-unstable lesions.”
BackgroundPolymorphisms of the BRAF gene predispose males to malignant melanoma.
Meyer, P., Sergi, C. M., & Garbe, C. (2003) · Journal of Carcinogenesis · doi:10.1186/1477-3163-2-7 · Cited by 44
Molecular Genetic Analysis of 103 Sporadic Colorectal Tumours in Czech Patients
Vasovčák, P., Pavlikova, K., Sedláček, Z., Škapa, P., Kouda, M., Hoch, J., & Křepelová, A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024114 · Cited by 43
“These changes were rarely if ever seen in HNPCC tumours, and may be mutually exclusive with KRAS mutations [29].”
Clinical Genetics of Hereditary Colorectal Cancer
Power, D. G., Glogowski, E., & Lipkin, S. M. (2010) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2010.06.006 · Cited by 49
Mutual exclusiveness between PIK3CA and KRAS mutations in endometrial carcinoma
Kang, S., Seo, S., Chang, H. J., Yoo, C. W., Park, S. Y., & Dong, S. (2008) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2007.01172.x · Cited by 43
Takahashi, K., Eguchi, H., Arihiro, K., Ito, R., Koyama, K., Soda, M., COLOGNE, J. B., Hayashi, Y., Nakata, Y., Nakachi, K., et al. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20277 · Cited by 47
PIK3CA alterations in Middle Eastern ovarian cancers
Abubaker, J. A., Bavi, P. P., Al‐Haqawi, W., Jehan, Z., Munkarah, A. R., Shahab Uddin, M. S., & Al-Kuraya, K. S. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-51 · Cited by 43
“This also supports the view that BRAF and KRAS mutations have equivalent effects on tumorigenesis [ 44-46 ].”
ResultMaruyama, R., Akino, K., Toyota, M., Suzuki, H., Imai, T., Ohe-Toyota, M., Yamamoto, E., Nojima, M., Fujikane, T., Sasaki, Y., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn060 · Cited by 47
Prognostic impact of mutation profiling in patients with stage II and III colon cancer
Shen, Y., Han, X., Wang, J., Wang, S., Yang, H., Lu, S.-H., & Shi, Y. (2016) · Scientific Reports · doi:10.1038/srep24310 · Cited by 48
Serrated neoplasia of the colorectum
Harvey, N. T. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i28.3792 · Cited by 43
“KRAS and BRAF mutations appear to be mutually exclusive within both polyps and carcinomas [ 41-43 ]”
BackgroundPark, H., Kang, H. C., Kim, I., Jang, S., Kim, K., Yoon, H., Jeong, S., & Park, J. (2006) · International Journal of Cancer · doi:10.1002/ijc.22276 · Cited by 43
“The BRAF V600E and K-ras mutations are known to be mutually exclusive.(9,10)”
BackgroundGene expression deregulation by KRAS G12D and G12V in a BRAF V600E context
Monticone, M., Biollo, E., Maffei, M., Donadini, A., Romeo, F., Storlazzi, C. T., Giaretti, W., & Castagnola, P. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-92 · Cited by 47
“In particular, BRAF mutations were more often found in premalignant colon polyps and in early, rather than in advanced, CRC [18, 23-25 ].”
BackgroundWhat makes oncogenes mutually exclusive?
Cisowski, J., & Bergö, M. O. (2016) · Small GTPases · doi:10.1080/21541248.2016.1212689 · Cited by 51
Clinical Application of Genetics in Management of Colorectal Cancer
Kim, E. R., & Kim, Y.-H. (2014) · Intestinal Research · doi:10.5217/ir.2014.12.3.184 · Cited by 43
“org BRAF mutation and MLH1 methylation.(14,31,32)”
Zhao, J., & Luo, Z. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23095158 · Cited by 47
Mutations in BRAF correlate with poor survival of colorectal cancers in Chinese population
Liou, J., Wu, M., Shun, C., Chiu, H., Chen, M., Chen, C.-C., Wang, H., Lin, J., & Liang, J. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1229-1 · Cited by 44
“Mutations of KRAS and BRAF genes occur mutually exclusive in CRC [5, 6].”
BackgroundCushman-Vokoun, A. M., Stover, D. G., Zhao, Z., Koehler, E. A., Berlin, J. D., & Vnencak-Jones, C. L. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.04.005 · Cited by 24
“Clinical Colorectal Cancer September 2013 previous data suggesting that these mutations are typically mutually exclusive.(8,34,35)”
Dasari, A. N., & Messersmith, W. A. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2283 · Cited by 48
“BRAF mutations also seem to be associated with right-sided tumors with sporadic microsatellite instability (MSI) and CpG island methylator phenotype (9, 31, 32).”
BackgroundEpithelial Neoplasms of the Large Intestine
Redston, M. S. (2009) · Elsevier eBooks · doi:10.1016/b978-141604059-0.50026-6 · Cited by 47
Wu, M., Semba, S., Oue, N., Ikehara, N., Yasui, W., & Yokozaki, H. (2004) · Gastric Cancer · doi:10.1007/s10120-004-0300-9 · Cited by 43
“Almost all BRAF mutations have been reported within two kinase domains (G-loop domain and kinase domain), and the most common mutation is a single substitution, V599E [5-8].”
InfluentialPerren, A. A., Schmid, S., Locher, T., Saremaslani, P., Bonvin, C., Heitz, P. U., & Komminoth, P. (2004) · Endocrine Related Cancer · doi:10.1677/erc.1.00841 · Cited by 42
“In colon carcinomas, BRAF mutations were only found in tumors without K-RAS mutations, indicating an equivalent tumorigenic effect (Davies et al. 2002, Rajagopalan et al. 2002 ).”
BackgroundUpdate on Molecular Diagnostics in Thyroid Pathology: A Review
Alzumaili, B., & Sadow, P. M. (2023) · Genes · doi:10.3390/genes14071314 · Cited by 48
“The inverse association between BRAF and RAS in alternative activation of MEK/MAPK signaling in many tumors [35], including colon [36] and ovarian tumors [37], inspired Cohen et al.”
BackgroundPIK3CA mutations mostly begin to develop in ductal carcinoma of the breast
Li, H., Zhu, R., Wang, L., Zhu, T., Li, Q., Chen, Q., Wang, H., & Zhu, H. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.09.016 · Cited by 42
Kim, I.-J., Kang, H. C., Jang, S., Kim, K. H., Ahn, S.-A., Yoon, H., Yoon, S. N., & Park, J.-G. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi237 · Cited by 38
Human Colorectal Cancer from the Perspective of Mouse Models
Šťastná, M., Janečková, L., Hrčkulák, D., Kříž, V., & Kořínek, V. (2019) · Genes · doi:10.3390/genes10100788 · Cited by 46
Kawaguchi, Y., Kopetz, S., Kwong, L. N., Xiao, L., Morris, J. S., Cao, H. S. T., Tzeng, C.-W. D., Chun, Y. S., Lee, J. E., & Vauthey, J. (2021) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2021.05.027 · Cited by 42
Mutations of BRAF and KRAS in gastric cancer and their association with microsatellite instability
Zhao, W., Chan, T. L., Chu, K., Chan, A. S. Y., Stratton, M. R., Yuen, S. T., & Leung, S. Y. (2003) · International Journal of Cancer · doi:10.1002/ijc.11553 · Cited by 41
Lynch or Not Lynch? Is that Always a Question?
Colas, C., Coulet, F., Svrcek, M., Collura, A., Fléjou, J., Duval, A., & Hamelin, R. (2012) · Advances in cancer research · doi:10.1016/b978-0-12-394280-7.00004-x · Cited by 42
Huang, M. C., Cheong, W. C., Lim, L. S., & Li, M. (2012) · Electrophoresis · doi:10.1002/elps.201100460 · Cited by 40
Current Tissue Molecular Markers in Colorectal Cancer: A Literature Review
Peluso, G., Incollingo, P., Calogero, A., Tammaro, V., Rupealta, N., Chiacchio, G., Sotelo, M. L. S., Minieri, G., Pisani, A., Riccio, E., et al. (2017) · BioMed Research International · doi:10.1155/2017/2605628 · Cited by 46
“The result is cell survival, proliferation, and metastasis [25].”
BackgroundFrattini, M., Perrone, F., Suardi, S., Balestra, D., Caramuta, S., Colombo, F., Licitra, L. F., Cantù, G., Pierotti, M. A., & Pilotti, S. (2006) · Head & Neck · doi:10.1002/hed.20433 · Cited by 40
Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction
Turner, D. J., Zirvi, M., Barany, F., Elenitsas, R., & Seykora, J. T. (2005) · Journal of Cutaneous Pathology · doi:10.1111/j.0303-6987.2005.00338.x · Cited by 40
“The BRAF gene acts immediately downstream of the RAS proto-oncogene and upstream of the MAP kinases.(4,22) The discovery that the BRAF exon 15 V600E mutation was present in approximately 68%”
BackgroundMethodBRAF Mutation Testing in Colorectal Cancer
Sharma, S. G., & Gulley, M. L. (2010) · Archives of Pathology & Laboratory Medicine · doi:10.5858/2009-0232-rs.1 · Cited by 38
Abdel‐Maksoud, M. S., El–Gamal, M. I., Lee, B. S., El‐Din, M. M. G., Jeon, H. R., Kwon, D., Ammar, U. M., Mersal, K. I., Ali, E. M. H., Lee, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00230 · Cited by 40
Somatic BRAF-V600E Mutations in Familial Colorectal Cancer
Vandrovcová, J., Lagerstedt‐Robinson, K., Påhlman, L., & Lindblom, A. (2006) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-06-0359 · Cited by 39
“This V600E mutation is frequent and accounts for up to 90% of all BRAF mutations in colorectal cancer (2, 3).”
BackgroundMethodInfluentialOxidative Stress Plays a Critical Role in Inactivating Mutant BRAF by Geldanamycin Derivatives
Fukuyo, Y., Inoue, M., Nakajima, T., Higashikubo, R., Horikoshi, N. T., Hunt, C. R., Usheva, A., Freeman, M. L., & Horikoshi, N. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6602 · Cited by 39
Menigatti, M., Cattaneo, E., Sabates–Bellver, J., Ilinsky, V. V., Went, P., Buffoli, F., Márquez, V. E., Jiricny, J., & Marra, G. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-124 · Cited by 40
Tie, J., & Desai, J. (2014) · Targeted Oncology · doi:10.1007/s11523-014-0330-0 · Cited by 39
“The “oncogenic addiction” of the MAPK pathway in colorectal cancer is reflected by the frequent perturbation of this pathway in this malignancy, with EGFR amplification and expression reported in up to 18 % [53, 54] and 62 % of cases [54–56], respectively, and activating mutations in KRAS and BRAF reported in 30–50 an…”
BackgroundNaghibalhossaini, F., Hosseini, H. M., Mokarram, P., & Zamani, M. (2011) · Pathology & Oncology Research · doi:10.1007/s12253-011-9388-5 · Cited by 38
“sporadic CRCs, more than 80% of which are in the hot spot of exon 15, resulting in V600E substitution [6–8].”
BackgroundPalomba, G., Colombino, M., Contu, A. S., Massidda, B., Baldino, G., Pazzola, A., Ionta, M. T., Capelli, F., Trova, V., Sedda, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-178 · Cited by 40
Levidou, G., Saetta, A. A., Gigelou, F., Κάρλου, Μ., Papanastasiou, P., Stamatelli, A., Kavantzas, N., Michalopoulos, N. V., Agrogiannis, G. D., Patsouris, E., et al. (2012) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-10-47 · Cited by 38
Dvorak, K., Higgins, A., Palting, J. D., Cohen, M. J., & Brunhoeber, P. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0344-x · Cited by 42
Genetic and epigenetic changes in aberrant crypt foci and serrated polyps
Suehiro, Y., & Hinoda, Y. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00784.x · Cited by 38
Watari, A., Takaki, K., Higashiyama, S., Li, Y., Satomi, Y., Takao, T., Tanemura, A., Yamaguchi, Y., Katayama, I., Shimakage, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209732 · Cited by 37
“It is well known that the K-Ras, NRas and BRAF genes are frequently mutated and activated in melanoma and stomach cancer (Davies et al., 2002; Rajagopalan et al., 2002).”
BackgroundDetecting recurrent gene mutation in interaction network context using multi-scale graph diffusion
Babaei, S., Hulsman, M., Reinders, M. J. T., & de Ridder, J. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-29 · Cited by 38
“Other examples include Raf1 and Ptk2 in the Pik3-cluster [38].”
BackgroundChou, C.-C., Chou, M.-J., & Tzen, C. (2008) · Medical Oncology · doi:10.1007/s12032-008-9124-5 · Cited by 37
“BRAF somatic mutations were reported in [60% of malignant melanomas [13], 29–83% of papillary carcinoma of the thyroid [14, 15], and in \15% of colorectal [13, 16], and ovarian cancers [13].”
BackgroundWangefjord, S., Sundström, M., Zendehrokh, N., Lindquist, K., Nodin, B., Jirström, K., & Eberhard, J. (2013) · Biology of Sex Differences · doi:10.1186/2042-6410-4-17 · Cited by 36
Bağcı, B., Sari, M., Karadayı, K., Turan, M., Özdemir, Ö., & Bağcı, G. (2016) · Cancer Biomarkers · doi:10.3233/cbm-160624 · Cited by 40
“Until today, a lot of oncogene mutations and tumor suppressor gene promoter hypermethylations were evaluated and the roles of these genes in colorectal carcinogenesis were tried to define [37,49].”
BackgroundBRAF-Directed Therapy in Metastatic Colorectal Cancer
Korphaisarn, K., & Kopetz, S. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000189 · Cited by 39
“Data from translation and preclinical studies suggest that Wnt pathway signals together with EGFR-MAPK pathway may promote tumor growth in BRAF V600E CRC.35 A clinical trial with a small molecule porcupine inhibitor, a Wnt inhibitor, combined with BRAF and EGFR inhibition is ongoing.”
BackgroundInfluentialMuta, Y., Matsuda, M., & Imajo, M. (2019) · Cancers · doi:10.3390/cancers11040513 · Cited by 37
BRAFmutation testing in clinical practice
Ziai, J. M., & Hui, P. (2012) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.12.1 · Cited by 43
Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations
Grady, W. M., Willis, J. E., Trobridge, P. A., Romero–Gallo, J., Muñoz, N. M., Olechnowicz, J., Ferguson, K., Gautam, S., & Markowitz, S. D. (2005) · International Journal of Cancer · doi:10.1002/ijc.21399 · Cited by 37
Molecular genetics of papillary thyroid carcinoma: great expectations...
Trovisco, V., Soares, P., Preto, A., Castro, P., Máximo, V., & Sobrinho-Simões, M. A. (2007) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302007000500002 · Cited by 48
Robbs, B. K., Lucena, P. I., & Viola, J. P. B. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.04.003 · Cited by 37
Mutations of the BRAF gene in ulcerative colitis‐related colorectal carcinoma
Aust, D. E., Haase, M., Dobryden, L., Markwarth, A., Löhrs, U., Wittekind, C., Baretton, G. B., & Tannapfel, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20925 · Cited by 37
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitors
Berger, D. M., Torres, N., Dutia, M. D., Powell, D. W., Ciszewski, G., Gopalsamy, A., Levin, J. I., Kim, K., Xu, W., Wilhelm, J., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.10.049 · Cited by 37
Harada, K., Hiraoka, S., Kato, J., Horii, A., Fujita, H., Sakaguchi, K., & Shiratori, Y. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6604014 · Cited by 37
“(Davies et al, 2002; Rajagopalan et al, 2002; Yuen et al, 2002).”
BackgroundFrom Ras signalling to ChoK inhibitors: a further advance in anticancer drug design
de Molina, A. R. (2003) · Cancer Letters · doi:10.1016/j.canlet.2003.08.031 · Cited by 37
Detection of genetic alterations in hereditary colorectal cancer screening
Pineda, M., González, S., Lázaro, C., Blanco, I., & Capellá, G. (2009) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2009.11.002 · Cited by 49
Pediatric Brain Tumors: Current Knowledge and Therapeutic Opportunities
Glod, J. W., Rahme, G. J., Kaur, H., Raabe, E. H., Hwang, E. I., & Israel, M. A. (2016) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000551 · Cited by 37
The significance of gene mutations across eight major cancer types
Paul, P., Malakar, A. K., & Chakraborty, S. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2019.04.004 · Cited by 41
DNA Methylation Profiles of Female Steroid Hormone-Driven Human Malignancies
Campan, M., Weisenberger, D. J., & Laird, P. W. (2006) · Springer eBooks · doi:10.1007/3-540-31181-5_8 · Cited by 37
Krikelis, D., Skoura, E. V., Kotoula, V., Rondogianni, P., Pianou, N. K., Samartzis, A. P., Xanthakis, I., Fountzilas, G., & Datseris, I. (2014) · PubMed · Cited by 37
Sheu, J. J., Guan, B., Tsai, F., Hsiao, E. Y.-T., Chen, C., Seruca, R., Wang, T., & Shih, I. (2012) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.11.026 · Cited by 42
Naik, J., Seligmann, J. F., & Perren, T. J. (2011) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2011-200320 · Cited by 36
“In a large series of colorectal cancers, the prevalence of a KRAS mutation was observed in 51%, similar to the rate suggested for mEOCs.(13) Additionally, activating missense mutations in one of the downstream genes, BRAF, has been commonly found in cancers known to exhibit RAS mutations, but within a single tumour th…”
Molecular Mechanism of SLC5A8 Inactivation in Breast Cancer
Elangovan, S., Pathania, R., Ramachandran, S., Ananth, S., Padia, R. N., Srinivas, S. R., Babu, E., Hawthorn, L., Schoenlein, P. V., Boettger, T., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01702-12 · Cited by 35
“BRAF, a member of the RAF family of serine/threonine kinases, mediates cellular responses to growth signals through the RAS/RAF/MAPK signaling pathway (57, 58), and BRAF-activating mutations have been reported in more than 70% of cancers (59, 60).”
BackgroundLewandowska, M. A., Jóźwicki, W., & Żurawski, B. A. (2013) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-013-0025-8 · Cited by 37
“[11], in the systematic evaluation of KRAS and BRAF mutations, demonstrated that both genes are mutated at a similar phase of tumorigenesis: after initiation but before malignant conversion.”
BackgroundFunction of RasGRP3 in the formation and progression of human breast cancer
Nagy, Z. S., Kovács, I., Török, M., Tóth, D., Vereb, G., Buzás, K., Juhász, I., Blumberg, P. M., Bíró, T., & Czifra, G. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-96 · Cited by 42
Wu, M., Kim, Y. S., Ryu, H.-S., Choi, S. C., Kim, K. Y., Park, W. C., Kim, M. S., Myung, J. Y., Choi, H. S., Kim, E. J., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152791 · Cited by 36
Mechanisms of resistance to anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer
Saridaki, Z., Georgoulias, V., & Souglakos, J. (2010) · World Journal of Gastroenterology · doi:10.3748/wjg.v16.i10.1177 · Cited by 38
Lack of BRAFV600E Mutations in Giant Congenital Melanocytic Nevi in a Chinese Population
Wu, D., Wang, M., Wang, X., Yin, N., Song, T., Li, H., Yu, J., Wang, D.-M., & Zhao, Z. (2011) · American Journal of Dermatopathology · doi:10.1097/dad.0b013e3181fb5bc7 · Cited by 36
“Previously published studies have indicated that the BRAF and NRAS codon 61 mutations are mutually exclusive in colorectal cancer and melanomas.(6,22,23) The RAF genes encode for cytoplasmic serine/threonine kinases that are regulated by binding RAS proteins.”
BackgroundCaruso, M., Moore, J., Goodall, G. J., Thomas, M., Phillis, S., Tyskin, A., Cheetham, G., Lerda, N., Takahashi, H., & Ruszkiewicz, A. (2009) · Virchows Archiv · doi:10.1007/s00428-009-0731-0 · Cited by 34
“The V600E BRAF mutation (previously reported as V599E) in the kinase domain [62, 63] mimics regulatory phosphorylation and leads to the constitutive activation of the MAP kinase pathway, independent of KRAS activation [64].”
BackgroundResultGenetic and Epigenetic Analysis of erbB Signaling Pathway Genes in Lung Cancer
Hoque, M. O., Brait, M., Rosenbaum, E., Poeta, M. L., Pal, P., Begum, S., Dasgupta, S., Carvalho, A. L., Ahrendt, S. A., Westra, W. H., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181f77a53 · Cited by 34
Kang, S., Lee, J. M., Jeon, E., Lee, S., Kim, H., Kim, H., Seo, S., Park, S., Sidransky, D., & Dong, S. M. (2006) · International Journal of Cancer · doi:10.1002/ijc.21991 · Cited by 34
“Primer pairs specific for methylated and unmethylated DNA of hMLH1 and RASSF1A were listed, as previously described.(10,28)”
BackgroundResultPredictive and Prognostic Factors in Colorectal Cancer: A Personalized Approach
Kulendran, M., Stebbing, J. F., Marks, C. G., & Rockall, T. (2011) · Cancers · doi:10.3390/cancers3021622 · Cited by 36
“They are mutually exclusive of KRAS mutations and are thus a candidate for an independent biomarker for CRC [58].”
BackgroundActivation of Jun N-terminal kinase is a mediator of vincristine-induced apoptosis of melanoma cells
Zhu, B.-K., Wang, P., Zhang, X. D., Jiang, C. C., Chen, L. H., Avery‐Kiejda, K. A., Watts, R. N., & Hersey, P. (2008) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3282f3138a · Cited by 35
Molecularly targeted agents: Their promise as cancer chemopreventive interventions
Thiery-Vuillemin, A., Nguyen, T., Pivot, X. B., Spano, J., Dufresnne, A., & Soria, J. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.005 · Cited by 39
Yan, L., Shi, J. H., & Zhu, J. (2024) · Discover Oncology · doi:10.1007/s12672-024-01163-1 · Cited by 45
Korphaisarn, K., Pongpaibul, A., Limwongse, C., Roothumnong, E., Klaisuban, W., Nimmannit, A., Jinawath, A., & Akewanlop, C. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.926 · Cited by 33
Serrated tubulovillous adenoma of the large intestine
Bettington, M. L., Walker, N. I., Rosty, C., Brown, I., Clouston, A. D., McKeone, D., Pearson, S., Klein, K., Leggett, B., & Whitehall, V. (2015) · Histopathology · doi:10.1111/his.12788 · Cited by 33
“Using immunohistochemistry, loss of expression of the mismatch repair enzyme MLH1, as expected, was not found in any sTVAs, as MSI secondary to MLH1 promoter methylation is correlated strongly with BRAF but not KRAS mutation.(28) In contrast, strong nuclear p53 staining (indicative of TP53 mutation(29)) was more frequ…”
BackgroundDiet, Microbiota, and Colorectal Cancer
Grazioso, T. P., Brandt, M., & Djouder, N. (2019) · iScience · doi:10.1016/j.isci.2019.10.011 · Cited by 39
Helderman, N. C., ten Broeke, S. W., Morreau, H. M., Suerink, M., Terlouw, D., Lam, A.-S. V. D. W.-’. T., van Wezel, T., & Nielsen, M. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103338 · Cited by 35
Tonello, M., Baratti, D., Sammartino, P., Giorgio, A. D., Robella, M., Sassaroli, C., Framarini, M., Valle, M., Macrì, A., Graziosi, L., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-11045-3 · Cited by 38
Epidermal Growth Factor Receptor Pathway Mutations and Colorectal Cancer Therapy
Grossmann, A. H., & Samowitz, W. S. (2011) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2011-0047-ra · Cited by 43
RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer
Pijnenborg, J. M. A., Veen, G. C. D.-D., Kisters, N., Delvoux, B., van Engeland, M., Herman, J. G., & Groothuis, P. G. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl455 · Cited by 33
Yamaguchi, T., Iijima, T., Mori, T., Takahashi, K., Matsumoto, H., Miyamoto, H., Hishima, T., & Miyaki, M. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0293-4 · Cited by 33
B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells
Kim, J.-S., Lee, C. S., Foxworth, A., & Waldman, T. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3862 · Cited by 33
“Interestingly, mutations of K-Ras and B-Raf were mutually exclusive in tumor types in which both occur, suggesting that K-Ras and B-Raf provide an equivalent or at least redundant oncogenic stimulus in cancer pathogenesis (3).”
BackgroundEdin, S., Gylling, B., Li, X., Stenberg, Å., Löfgren‐Burström, A., Zingmark, C., Guelpen, B. R. V., Ljuslinder, I., Ling, A., & Palmqvist, R. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02483-9 · Cited by 39
Shaw, P., Bhowmik, A. D., Pillai, M. S. G., Robbins, N., Dwivedi, S. K. D., & Rao, G. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217750 · Cited by 42
Therapeutic potential of siRNA and DNAzymes in cancer
Karnati, H. K., Yalagala, R. S., Undi, R. B., Pasupuleti, S. R., & Gutti, R. K. (2014) · Tumor Biology · doi:10.1007/s13277-014-2477-9 · Cited by 32
“Similar to RAS, mutations in RAF molecules were also observed in malignant tumors of the skin, colon, thyroid, and ovary [27, 28].”
ResultColorectal Cancer Microenvironment: Among Nutrition, Gut Microbiota, Inflammation and Epigenetics
Garagnani, P., Pirazzini, C., & Franceschi, C. (2012) · Current Pharmaceutical Design · doi:10.2174/1381612811306040765 · Cited by 39
“[25] Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein”
BackgroundBekaert, L., Emery, É., Levallet, G., & Lechapt, E. (2016) · Brain Tumor Pathology · doi:10.1007/s10014-016-0275-3 · Cited by 35
Cai, M., Liang, X., Sun, X., Chen, H., Dong, Y., Wu, L., Gu, S., & Han, S. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00164 · Cited by 30
Moradi, A., Pourseif, M. M., Jafari, B., Parvizpour, S., & Omidi, Y. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104790 · Cited by 37
Metadata
- Authors
- Rajagopalan, H., Bardelli, A., Lengauer, C., Kinzler, K. W., Vogelstein, B., & Velculescu, V. E.
- Affiliations
- Johns Hopkins University (US)
- Howard Hughes Medical Institute (US)
- Corresponding author
- Velculescu, Victor E.
- Venue
- Nature
- Published
- 2002-08-29
- Volume
- 418
- Issue
- 6901
- Pages
- 934-934
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1985035689
- Cited by
- 1,224
- References
- 8
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 29 · 2023: 30 · 2022: 26 · 2021: 42 · 2020: 38 · 2019: 35 · 2018: 41 · 2017: 42 · 2016: 51 · 2015: 76 · 2014: 65 · 2013: 74 · 2012: 78
- FWCI
- 37.23
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- BRAF mutation, KRAS mutation, oncogenic Ras, DNA mismatch repair, colorectal cancer, melanoma, carcinogenesis, DNA repair, mutation spectrum, growth factor signaling
- MeSH terms
- DNA Damage, DNA Repair, Gene Frequency, Humans, Mutation, Oncogenes, Genes, ras, Colorectal Neoplasms, Proto-Oncogene Proteins c-raf, Base Pair Mismatch
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.